Drug intelligence / Profile preview

anti-PNAG vaccine

Development stage: Preclinical
Lead developer: Iaso Therapeutics
Modality: Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics

Overview

Anti-PNAG is an investigational cancer vaccine being developed by Iaso Therapeutics that targets poly-N-acetylglucosamine (PNAG), a polysaccharide expressed on certain cancer cells. The vaccine utilizes Iaso's proprietary mutant bacteriophage Qβ (mQβ) virus-like particle (VLP) platform technology to display PNAG antigens and provoke an immune response against PNAG-expressing cancer-related targets. The mQβ platform is designed to elicit superior antibody responses compared to conventional vaccine carriers. The vaccine has achieved validated proof of concept and is currently available for licensing.

Other names: anti-PNAG (Cancer)

Targets

PNAG (Poly-N-acetylglucosamine)

Beyond the preview

Go deeper on anti-PNAG vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-PNAG vaccine.

Explore the full profile